Brendan Manning, Ph.D.

Brendan Manning, Ph.D.

Professor and Acting Chair, Department of Molecular Metabolism (Harvard T.H. Chan School of Public Health
Affiliate Member of Cell Biology (HMS)

Brendan Manning, Ph.D. is a Professor and Acting Chair in the Department of Molecular Metabolism at the Harvard T.H. Chan School of Public Health. He received his PhD from Yale University in 2000 and was a postdoctoral fellow at Harvard Medical School. In 2004, Dr. Manning became the first faculty member hired in the then newly established Department of Genetics and Complex Diseases (later changed to Molecular Metabolism) at Harvard-Chan. Dr. Manning was an inaugural recipient of the National Cancer Institute’s Outstanding Investigator Award. 

Research in the Manning lab is defining the molecular interface between cellular signaling networks and metabolic networks, as it relates to both normal physiology and diseases with metabolic dysregulation as a key feature, including cancer, diabetes, and aging-related diseases. Research efforts are focused in part on defining the regulatory mechanisms and functions of a signaling network converging on the tuberous sclerosis complex (TSC) protein complex and the mammalian target of rapamycin (mTOR), which relay an array of extracellular and intracellular growth signals to control the balance between anabolic and catabolic metabolism in cells, tissues, and tumors.

665 Huntington Ave

SPH2-117

Boston, MA 02115

A relative quantitative positive/negative ion switching method for untargeted lipidomics via high resolution LC-MS/MS from any biological source.
Authors: Authors: Breitkopf SB, Ricoult SJH, Yuan M, Xu Y, Peake DA, Manning BD, Asara JM.
Metabolomics
View full abstract on Pubmed
Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.
Authors: Authors: Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, Hoxhaj G, Saghatelian A, Shaw RJ, Manning BD.
Cell Metab
View full abstract on Pubmed
Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegans.
Authors: Authors: Heintz C, Doktor TK, Lanjuin A, Escoubas C, Zhang Y, Weir HJ, Dutta S, Silva-García CG, Bruun GH, Morantte I, Hoxhaj G, Manning BD, Andresen BS, Mair WB.
Nature
View full abstract on Pubmed
Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1.
Authors: Authors: Ricoult SJ, Dibble CC, Asara JM, Manning BD.
Mol Cell Biol
View full abstract on Pubmed
Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.
Authors: Authors: Sahin M, Henske EP, Manning BD, Ess KC, Bissler JJ, Klann E, Kwiatkowski DJ, Roberds SL, Silva AJ, Hillaire-Clarke CS, Young LR, Zervas M, Mamounas LA.
Pediatr Neurol
View full abstract on Pubmed
Emerging role of mTOR in the response to cancer therapeutics.
Authors: Authors: Ilagan E, Manning BD.
Trends Cancer
View full abstract on Pubmed
CASTORing New Light on Amino Acid Sensing.
Authors: Authors: Hallett JEH, Manning BD.
Cell
View full abstract on Pubmed
Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.
Authors: Authors: Ricoult SJ, Yecies JL, Ben-Sahra I, Manning BD.
Oncogene
View full abstract on Pubmed
Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation.
Authors: Authors: Covarrubias AJ, Aksoylar HI, Yu J, Snyder NW, Worth AJ, Iyer SS, Wang J, Ben-Sahra I, Byles V, Polynne-Stapornkul T, Espinosa EC, Lamming D, Manning BD, Zhang Y, Blair IA, Horng T.
Elife
View full abstract on Pubmed
mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle.
Authors: Authors: Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD.
Science
View full abstract on Pubmed